Mirtazapina Aurovitas (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Aurovitas, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. It belongs to the class of noradrenergic and specific serotonergic antidepressants and is indicated for patients who require an alternative to selective serotonin reuptake inhibitors.

GNH USA supplies Mirtazapina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mirtazapine is used primarily in the treatment of depressive disorders, acting on noradrenergic and serotonergic pathways. - Major depressive disorder: reduction of depressive symptoms in adult patients. - Depressive episodes with insomnia: improvement of sleep quality and appetite. - Depressive disorder with anxiety: alleviation of anxiety and mood symptoms.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Increased appetite: heightened hunger leading to weight gain. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed intestinal transit.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating possible anaphylaxis. - Suicidal thoughts: emergence or worsening of suicidal ideation, especially in early treatment.

Before prescribing mirtazapine, clinicians should consider several safety precautions. - Assess psychiatric history: evaluate risk of suicidal ideation, especially in young adults. - Monitor weight changes: track body weight and appetite due to potential gain. - Review hepatic function: adjust use in patients with liver impairment. - Caution with CNS depressants: avoid concurrent use with alcohol or sedatives that may enhance drowsiness. - Pregnancy and lactation: consider limited data and weigh benefits against potential risks. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Mirtazapine can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; avoid concomitant use. - Strong CYP3A4 inhibitors: may increase mirtazapine plasma levels, leading to toxicity. - CNS depressants: combined sedation and respiratory depression risk.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates: mirtazapine may alter metabolism of drugs like fluoxetine. - Anticholinergic agents: additive dry mouth and constipation. - Alcohol: enhances sedative effects, requiring caution.